Mousavi Seyedeh Zahra, Harris Ethan R, Agarwal Sanjana, Saha Prasenjit, Glenn Eve R, Fox Henry M, Srikumaran Umasuthan
The Department of Orthopaedic Surgery, The Johns Hopkins University, Baltimore, MD, USA.
School of Medicine, The Johns Hopkins University, Baltimore, MD, USA.
JSES Int. 2025 May 14;9(4):1345-1351. doi: 10.1016/j.jseint.2025.04.022. eCollection 2025 Jul.
While estrogen is essential for bone remodeling, its impact on joint health is more nuanced. Previous studies suggest that high estrogen states, including those induced by estrogen replacement therapy (ERT), are associated with osteoarthritis and an increased risk of revisions after hip and/or knee arthroplasty. Given the rise in total shoulder arthroplasty (TSA) cases, it is important to investigate factors that may impact its outcomes. This study aimed to evaluate whether ERT use impacts TSA outcomes at 2, 4, and 10 years postoperatively.
This was a retrospective cohort study of females aged ≥55 years who underwent TSA, using the TriNetX Research Network. Patients were stratified by ERT use for at least 1-5 years preoperatively. One-to-one propensity score matching was performed based on age, race, bone density, osteoarthritis, and other comorbidities. Primary outcomes were revision rates at 2, 4, and 10 years. Secondary outcomes included prosthetic joint infections, mechanical complications, and shoulder instability, as well as 90-day postoperative medical complications. Tests of significance and risk ratios (RR) were calculated to compare outcomes with an alpha of <0.05.
After matching, 1,779 patients were included in each group. At 90 days, the ERT cohort had a higher risk of deep vein thrombosis (RR =1.91; = .012). At 2 and 4 years postoperatively, the ERT group had a significantly higher risk of revisions (RR = 1.71 and 1.59, respectively), shoulder instability (RR = 1.81 and 1.80), and overall mechanical complications (RR = 1.60 and 1.67). At 10 years, the risk for revisions (RR = 1.59; = .002) and mechanical complications (RR = 1.43; = .005) persisted.
Our findings suggest that ERT is associated with long-term increased risk of revision procedures and mechanical complications following TSA. This demonstrates the complex relationship between estrogen and bone health, highlighting the need for future studies investigating the impact of ERT on implant survival and osseointegration.
虽然雌激素对骨重塑至关重要,但其对关节健康的影响更为微妙。先前的研究表明,高雌激素状态,包括雌激素替代疗法(ERT)诱导的状态,与骨关节炎以及髋和/或膝关节置换术后翻修风险增加有关。鉴于全肩关节置换术(TSA)病例的增加,研究可能影响其结果的因素很重要。本研究旨在评估ERT的使用是否会影响术后2年、4年和10年的TSA结果。
这是一项使用TriNetX研究网络对年龄≥55岁接受TSA的女性进行的回顾性队列研究。患者根据术前至少1至5年使用ERT进行分层。根据年龄、种族、骨密度、骨关节炎和其他合并症进行一对一倾向评分匹配。主要结局是2年、4年和10年的翻修率。次要结局包括人工关节感染、机械并发症、肩关节不稳定以及术后90天的医疗并发症。计算显著性检验和风险比(RR)以比较结局,α<0.05。
匹配后,每组纳入1779例患者。在90天时,ERT队列发生深静脉血栓形成的风险更高(RR = 1.91;P = 0.012)。术后2年和4年,ERT组翻修风险(分别为RR = 1.71和1.59)、肩关节不稳定(RR = 1.81和1.80)以及总体机械并发症(RR = 1.60和1.67)显著更高。在10年时,翻修风险(RR = 1.59;P = 0.002)和机械并发症风险(RR = 1.43;P = 0.005)仍然存在。
我们的研究结果表明,ERT与TSA术后长期翻修手术风险增加和机械并发症有关。这表明雌激素与骨骼健康之间存在复杂关系,凸显了未来研究ERT对植入物存活和骨整合影响的必要性。